Tamiflu, Paxlovid, Molnupiravir, Remdesivir, Corona vaccinations: Miracle drugs with zero effect

Tamiflu, Paxlovid, Molnupiravir, Remdesivir, COVID-19 vaccines: five products, one script. The government, in a panic, buys billions, the manufacturer provides the studies along with the vaccines, the raw data remains under wraps until a court or an expiring patent forces its release. And by the time the truth finally comes out, the vaccines have long since been paid for, distributed, and, in some cases, destroyed.

Tamiflu: 160,000 pages for half a day less of a runny nose

Bird flu in 2005, swine flu in 2009, and Roche had the pill to combat it. The German Federal Ministry of Health alone spent €68,7 million and stockpiled enough active ingredient powder for 7,5 million treatment doses in 2009. According to the BMJ, the drug generated over $18 billion worldwide for the Basel-based company, with 96 countries holding stockpiles for 350 million people in 2009. This was based on a six-page, manufacturer-funded meta-analysis of ten studies, eight of which were never published. The WHO, EMA, and CDC recommended and stockpiled the drug without ever having seen the raw data , while the FDA, which had seen it, had required Roche to include a warning in the package insert since 2000: Protection against complications had not been proven. The US stockpiled 65 million treatments for $1,3 billion, and Great Britain spent £424 million. Only after a four-year campaign did Roche release the complete study reports. Cochrane sifted through over 160,000 pages and found: less than a day shorter symptoms, no impact on hospital admissions, no reliable effect against pneumonia, but nausea, vomiting, and psychiatric side effects. A decade after completion, the majority of Roche's Phase III trials remained unpublished. The WHO downgraded the drug from its list of essential medicines in 2017, while the CDC left its recommendation unchanged, preferring to rely on observational studies. The German government declared in 2013 that this did not alter its "positive benefit/risk assessment." Who actually benefited from swine flu was already documented here in 2009.

The real bombshell came only after the patent expired. The publicly funded REMAP-CAP platform study randomized 442 intensive care patients with confirmed influenza: Without Tamiflu, 13,7 percent died within 90 days; with Tamiflu, 19,8 percent died. The probability of harm was 98 percent, and recruitment was halted. Two limitations must be considered: It is a preprint without peer review, and it applies only to intensive care units. Anyone who uses this to claim that "Tamiflu kills" every patient seen by a general practitioner has no evidence. Anyone who uses it to claim that "Tamiflu helps" still has no evidence after 27 years.

The same consultants, the same invoices

In 2010, the WHO was required to publish the names of its emergency committee members along with their declarations of interests : Arnold Monto declared consulting fees from Roche, GSK, Novartis, Baxter, and Sanofi; Neil Ferguson reported consulting work for Roche, Novartis, and GSK until 2007; and Nancy Cox reported receiving funds from the pharmaceutical industry association IFPMA for her CDC department. The WHO concluded there was no conflict of interest. Ten years later, Monto was the acting chairman of the FDA panel that granted emergency use authorization for the COVID-19 vaccines. The fact that industry-funded trials are about four times more likely to favor the sponsor has been documented in the BMJ since 2003. Anyone who calls such a body an independent body has either turned a blind eye or was paid to do so.

Paxlovid and Molnupiravir: Pills that did nothing

In 2022, Pfizer sold $18,9 billion worth of Paxlovid , citing an 89 percent reduction in hospitalizations among unvaccinated high-risk patients. Pfizer's own follow-up study, published 21 months after the press release, found no significant difference in vaccinated adults. The government-funded studies PANORAMIC and CanTreatCOVID confirmed in 2026: 0,8 percent hospitalizations or deaths with the pill, 0,7 percent without. Pfizer argues that the number of events is too small to draw any conclusions. Perhaps. But this very argument didn't bother anyone during the billion-dollar sales. For 2023, Pfizer itself anticipated a 58 percent drop in sales because governments were holding onto their stockpiles. Germany nevertheless ordered one million packs ; Pfizer Minister Lauterbach personally lobbied for the product. It hasn't been proven that Paxlovid kills people. What has been proven is that it simply does nothing for vaccinated individuals. And that's why it was bought.

Molnupiravir takes things a step further. At the end of 2021, the German Federal Ministry of Health procured around 80,000 treatment doses without EU approval. In February 2023, the EMA recommended rejection because clinical benefit had not been demonstrated. The manufacturer withdrew the application. And because the active ingredient intentionally mutates the virus, researchers discovered its mutation signature in global sequence databases in 2023, published in Nature, along with information shared with other people. A drug that doesn't cure but breeds new variants: purchase price kept secret, product in the trash.

Remdesivir and vaccination: Contract first, data later

On October 8, 2020, the European Commission signed a framework agreement with Gilead for up to 500,000 treatment cycles of Remdesivir. A week later, the WHO Solidarity study showed that the drug did not reduce mortality, and in November the WHO advised against its use. The final evaluation in 2022 found no effect in ventilated patients and only a small effect in others, which did not make the contract any cheaper. Information you should know about Remdesivir has been available here before.

Regarding vaccines, the FDA wanted to release Pfizer's regulatory documents for over 75 years; a federal judge ordered 55,000 pages per month . In Brussels, in 2025, the EU court overturned the Commission's refusal to release von der Leyen's text messages to Pfizer CEO Bourla because her statements were based on hypotheses and inconsistent information. Bioweapon, human experimentation, excess mortality : Let's still call it vaccination.

The screenplay has no end credits.

Five times the same story: panic, billion-dollar contract, manufacturer study, secrecy, disposal. The profits go to Basel, New York, and Foster City, the bill goes to you, the data is locked away. Roche never took back Tamiflu, Pfizer never paid, Merck never delivered on its promises. The pharmaceutical industry doesn't heal, it manages you until your death . And with the next pathogen, the same consultants will be sitting at the table again, signing the same contracts, and calling it "precaution"!